Malaria
Conditions
Interventions
SP Group Sulphadoxine Pyrimethamine arm
P group Proguanil arm
Sponsors
EDCTP
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: ¿ Pregnant women of all gravidity confirmed as having HbSS genotype. ¿ Screened after 16 weeks or onset of quickening, both aparasitaemic and parasitaemic at first enrolment. ¿ Must give informed written consent.
Exclusion criteria
Exclusion criteria: ¿ Known adverse drug reaction to any of the two medications (Sulphadoxine/Pyrimethamine and Proguanil). ¿ Co-existing medical disorders that may alter immunity such as diabetes mellitus (DM) and human immunodeficiency virus infection (HIV). ¿ Multiple gestations. ¿ Presence of severe clinical malaria at booking. ¿ Less than 16 weeks gestational age for Sulphadoxine/Pyrimethamine (SP) group. ¿ Use of antimalarials within the last one week prior to booking. ¿ Refusal to give informed written consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of malaria parasite at delivery | — |
Secondary
| Measure | Time frame |
|---|---|
| incidence of clinical malaria, incidence of malaria complications such as worsening maternal anaemia (haemoglobin concentration <10g/dl) and low birth weight (<2500g), adherence to medications and incidence of adverse drug events. | — |
Countries
Nigeria
Contacts
Public ContactOchuwa A. Babah
Senior Lecturer Consultant Obstetrician and Gynaecologist College of Medicine University of Lagos Lagos University Teaching Hospital Idi Araba Lagos Nigeria
Outcome results
None listed